Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Shares Outstanding (2016 - 2025)

Fate Therapeutics' Shares Outstanding history spans 14 years, with the latest figure at $115.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.26% year-over-year to $115.4 million; the TTM value through Dec 2025 reached $115.4 million, up 1.26%, while the annual FY2025 figure was $115.4 million, 1.26% up from the prior year.
  • Shares Outstanding reached $115.4 million in Q4 2025 per FATE's latest filing, roughly flat from $115.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $115.4 million in Q4 2025 to a low of $2.8 million in Q2 2025.
  • Average Shares Outstanding over 5 years is $83.9 million, with a median of $97.0 million recorded in 2022.
  • The largest YoY upside for Shares Outstanding was 4077.19% in 2025 against a maximum downside of 97.58% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $95.7 million in 2021, then crashed by 97.08% to $2.8 million in 2022, then skyrocketed by 3429.27% to $98.6 million in 2023, then grew by 15.51% to $113.9 million in 2024, then grew by 1.26% to $115.4 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Shares Outstanding are $115.4 million (Q4 2025), $115.3 million (Q3 2025), and $114.7 million (Q2 2025).